Pharmaceutical care for a case of tumor patient with interstitial lung disease due to EGFR-TKI and AIDS opportunistic infection

RAN Tuoyao; LI Chao

doi:10.6039/j.issn.1001-0408.2024.10.21

您当前的位置：

首页 >

文章列表页 >

Pharmaceutical care for a case of tumor patient with interstitial lung disease due to EGFR-TKI and AIDS opportunistic infection

更新时间：2025-09-25

- Pharmaceutical care for a case of tumor patient with interstitial lung disease due to EGFR-TKI and AIDS opportunistic infection
- ZHONGGUO YAOFANG Vol. 35, Issue 10, Pages: 1271-1275(2024)
- 作者机构：
  
  1.重庆市公共卫生医疗救治中心药学部，重庆　400036
  2.重庆大学附属肿瘤医院药学部，重庆　400030
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.10.21
  CLC： R969.3;R512.91
- Received：20 December 2023，
  
  Revised：2024-04-18，
  
  Accepted：23 April 2024，
  
  Published：30 May 2024
- 稿件说明：
移动端阅览
冉拓耀,李超.1例EGFR-TKI致间质性肺病合并艾滋病机会性感染肿瘤患者的药学服务[J].中国药房,2024,35(10):1271-1275.

RAN Tuoyao,LI Chao.Pharmaceutical care for a case of tumor patient with interstitial lung disease due to EGFR-TKI and AIDS opportunistic infection[J].ZHONGGUO YAOFANG,2024,35(10):1271-1275.
冉拓耀,李超.1例EGFR-TKI致间质性肺病合并艾滋病机会性感染肿瘤患者的药学服务[J].中国药房,2024,35(10):1271-1275. DOI： 10.6039/j.issn.1001-0408.2024.10.21.

RAN Tuoyao,LI Chao.Pharmaceutical care for a case of tumor patient with interstitial lung disease due to EGFR-TKI and AIDS opportunistic infection[J].ZHONGGUO YAOFANG,2024,35(10):1271-1275. DOI： 10.6039/j.issn.1001-0408.2024.10.21.

摘要

目的

为艾滋病合并肿瘤患者的药物治疗及药学监护提供参考。

方法

针对1例艾滋病合并肺腺癌患者靶向治疗过程中多次出现间质性肺病，且无法排除细菌、真菌感染的复杂病情，临床药师对该患者开展了用药监护、药物重整、不良反应监测等药学服务。

结果

该患者使用阿美替尼与间质性肺病等不良反应的相关性为“很可能相关”，临床药师建议暂停肿瘤靶向治疗药物，制定激素用药监护计划；针对有艾滋病机会性感染可能的病原菌，建议停用厄他培南、膦甲酸钠，监测伏立康唑血药浓度，随访伏立康唑安全性及抗真菌疗程；结合药物相互作用及患者自身状况，调整抗艾滋病药物为比克恩丙诺片；针对患者有肺孢子菌肺炎、血栓、胃黏膜损伤可能，建议予以复方磺胺甲噁唑、那屈肝素钙、艾司奥美拉唑等。医师均采纳临床药师建议。患者经治疗后转归良好，未见明显不良反应及药物相互作用，顺利出院。

结论

艾滋病合并肿瘤患者病情复杂、治疗药物多，临床药师可通过开展药物重整、治疗药物监测等手段对这类患者开展药物治疗管理，为患者提供个体化药学服务，保障用药安全。

Abstract

OBJECTIVE

To provide a reference for drug treatment and pharmaceutical care in AIDS patients with tumor.

METHODS

For a case of AIDS complicated with pulmonary adenocarcinoma， interstitial lung disease occurred repeatedly in the course of targeted therapy， and bacterial and fungal infections could not be ruled out. Clinical pharmacists provided pharmaceutical care such as medication monitoring， drug reconciliation， and adverse reaction monitoring for the patient.

RESULTS

The patient’s use of Amivantamab is “highly likely related” to adverse reactions such as interstitial lung disease， and it is recommended by the clinical pharmacist that the targeted therapy drugs should be suspended， and hormone medication monitoring plans should be formulated. For the possible pathogens of AIDS opportunistic infection， i

t was recommended to stop ertapenem and foscarnet sodium， monitor voriconazole concentration in blood and follow up on the safety and antifungal course of voriconazole. According to the drug-drug interaction and the patient’s condition， the anti-AIDS drug was adjusted to bictegravir sodium， emtricitabine and tenofovir alafenamide. For the possibility of

Pneumocystis carinii

pneumonia， thrombosis and gastric mucosal injury， preventive drugs such as Compound sulfamethoxazole， nadroparin calcium and esomeprazole were recommended. Physicians followed the advice of the clinical pharmacists. The patient made a good outcome after drug treatment without any significant adverse reactions or drug-drug interactions， and was discharged smoothly.

CONCLUSIONS

AIDS patients with tumor have complex disease condition and use many therapeutic drugs. Clinical pharmacists should conduct drug treatment management as drug reconciliation and medication monitoring and provide individual pharmaceutical care for these patients to guarantee the safety of drug use.

关键词

Keywords

references

Acquired Immunodeficiency Syndrome and Hepatitis C Professional Group ， Society of Infectious Diseases ， Chinese Medical Association ， Chinese Center for Disease Control and Prevention . Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome：2021 edition [J ] . Med J Peking Union Med Coll Hosp ， 2022 ， 13 （ 2 ）： 203 - 226 .

RECONDO G ， FACCHINETTI F ， OLAUSSEN K A ， et al . Making the first move in EGFR-driven or ALK-driven NSCLC：first-generation or next-generation TKI? [J ] . Nat Rev Clin Oncol ， 2018 ， 15 （ 11 ）： 694 - 708 .

OHMORI T ， YAMAOKA T ， ANDO K ， et al . Molecular and clinical features of EGFR-TKI-associated lung injury [J ] . Int J Mol Sci ， 2021 ， 22 （ 2 ）： 792 .

JOHKOH T ， LEE K S ， NISHINO M ， et al . Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors：a position paper from the Fleischner Society [J ] . Chest ， 2021 ， 159 （ 3 ）： 1107 - 1125 .

CHENG Y ， HE Y ， LI W ， et al . Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC：FLAURA China，a rando-mized study [J ] . Target Oncol ， 2021 ， 16 （ 2 ）： 165 - 176 .

YIN Y C ， SHU Y M ， ZHU J R ， et al . A real-world pharmacovigilance study of FDA Adverse Event Reporting System（FAERS）events for osimertinib [J ] . Sci Rep ， 2022 ， 12 （ 1 ）： 19555 .

LU S ， DONG X R ， JIAN H ， et al . AENEAS：a rando-mized phase Ⅲ trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations [J ] . J Clin Oncol ， 2022 ， 40 （ 27 ）： 3162 - 3171 .

LU S ， WANG Q M ， ZHANG G J ， et al . Efficacy of aumolertinib（HS-10296）in patients with advanced EGFR T790M+ NSCLC：updated post-national medical products administration approval results from the APOLLO regi-strational trial [J ] . J Thorac Oncol ， 2022 ， 17 （ 3 ）： 411 - 422 .

陈永邦，万宁，王冰，等 . 1例奥希替尼致间质性肺炎患者再用EGFR-TKI治疗的病例分析 [J ] . 中国药房， 2023 ， 34 （ 5 ）： 595 - 599 .

CHEN Y B ， WAN N ， WANG B ， et al . Case analysis of a patient with osimertinib-induced interstitial pneumonia who re-used EGFR-TKI therapy [J ] . China Pharm ， 2023 ， 34 （ 5 ）： 595 - 599 .

CHEN W Y ， ZHANG L J ， SHEN H ， et al . Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease：a case report and literature review [J ] . Anticancer Drugs ， 2023 ， 34 （ 3 ）： 460 - 466 .

DAI H P ， MA F ， REN Y H ， et al . Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease [J ] . Curr Med Sci ， 2023 ， 43 （ 1 ）： 1 - 12 .

SHENDEROV K ， COLLINS S L ， POWELL J D ， et al . Immune dysregulation as a driver of idiopathic pulmonary fibrosis [J ] . J Clin Invest ， 2021 ， 131 （ 2 ）： e143226 .

DUCHEMANN B ， DIDIER M ， PAILLER M C ， et al . Can nivolumab be used safely in idiopathic pulmonary fibrosis? [J ] . Rev Mal Respir ， 2019 ， 36 （ 2 ）： 209 - 213 .

中华医学会热带病与寄生虫学分会艾滋病学组 . 艾滋病合并侵袭性真菌病诊治专家共识 [J ] . 中华临床感染病杂志， 2019 ， 12 （ 4 ）： 253 - 267 .

AIDS Division of Tropical Diseases and Parasites Branch of Chinese Medical Association . Expert consensus on diag-nosis and treatment of HIV infection combined with invasive fungal diseases [J ] . Chin J Clin Infect Dis ， 2019 ， 12 （ 4 ）： 253 - 267 .

TAKESUE Y ， HANAI Y ， ODA K ， et al . Clinical practice guideline for the therapeutic drug monitoring of vorico-nazole in non-Asian and Asian adult patients：consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring [J ] . Clin Ther ， 2022 ， 44 （ 12 ）： 1604 - 1623 .

ABOUREHAB M A S ， ALQAHTANI A M ， YOUSSIF B G M ， et al . Globally approved EGFR inhibitors：insights into their syntheses，target kinases，biological activities， receptor interactions，and metabolism [J ] . Molecules ， 2021 ， 26 （ 21 ）： 6677 .

徐蕾，张伟霞，许倍铭，等 . 那屈肝素临床应用药学专家意见 [J ] . 上海医药， 2022 ， 43 （ 21 ）： 12 - 17 .

XU L ， ZHANG W X ， XU B M ， et al . Opinions of pharmaceutical experts on clinical application of nadroparin [J ] . Shanghai Med Pharm J ， 2022 ， 43 （ 21 ）： 12 - 17 .

质子泵抑制剂预防性应用专家共识写作组 . 质子泵抑制剂预防性应用专家共识：2018 [J ] . 中国医师杂志， 2018 ， 20 （ 12 ）： 1775 - 1781 .

Expert Consensus Writing Group on the Prophylactic Application of Proton Pump Inhibitors . Expert consensus on the preventive application of proton pump inhibitors：2018 [J ] . J Chin Physician ， 2018 ， 20 （ 12 ）： 1775 - 1781 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmaceutical care for the HIV-negative patient with disseminated Talaromyces marneffei osteomyelitis complicated by pulmonary tuberculosis

Expert consensus on rational medication management of targeted PI3K/Akt/mTOR inhibitors in breast cancer

Individualized treatment and pharmaceutical care for breast cancer complicated with chronic kidney disease

Pharmaceutical care of anti-infective treatment for a case of pulmonary infection due to Alternaria alternata after renal transplantation

Anticoagulation therapy analysis and pharmaceutical care for a breast cancer patient with pulmonary thromboembolism accompanied by multiple comorbidities

Related Author

ZHANG Qinghua

HE Liting

Writing Group of Expert Consensus on Rational Medication Management of Targeted PI3K/Akt/mTOR Inhibitors in Breast Cancer

任天舒

赵庆春

ZHANG Ming

YU Lu

WU Xudong

Related Institution

Dept. of Pharmacy， Jiangmen Central Hospital

Dept. of Internal Medicine， Zhonggongmiao Community Hospital of Ningbo Yinzhou District No.2 Hospital Medical Community

Dept. of Clinical Pharmacy， Ningbo Yinzhou District No.2 Hospital

Dept. of Pharmacy， Tangshan Maternal and Child Health Hospital

Dept. of Pharmacy， Tianjin Anding Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰